Pharmafile Logo
Pharmafocus logo
Advanced Search
Takeda building

Takeda acquire Maverick in $525m deal to expand cancer therapy portfolio

March 10, 2021
Research and Development Maverick, Takeda, cancer treatment

Takeda has acquired Maverick Therapeutics in a deal worth up to $525 million, in order to expand its portfolio of …

News
evonik__chemie_foto_001

Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate

March 10, 2021
Research and Development Alzheimer's, Cassava Sciences, Evonik

Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for …

News

Affinivax receives $22m funding for development of Staphylococcus aureus vaccine

March 10, 2021
Research and Development Affinivax, bacteria, vaccines

Affinivax has received an award of $22 million funding from CARB-X, a global non-profit organisation, to develop a vaccine targeting Staphylococcus …

News

CytoDyn’s COVID-19 treatment shows positive results in Phase III trial

March 9, 2021
Manufacturing and Production cytodyn, phase 3 trial, vyrologix

Biotechnology company CytoDyn has shown positive results in its Phase III CD12 trial of Vyrologix, its treatment for COVID-19 patients …

News
FDA building

FDA approves Kite’s Yescarta therapy for follicular lymphoma

March 9, 2021
Manufacturing and Production FDA, Kite, Yescarta

The FDA has granted accelerated approval to Kite’s Yescarta treatment, a medicine for adult patients with relapsed or refractory follicular …

News
nuts-1736520_1920

Camallergy awarded £1.1m government funding for peanut allergy immunotherapy

March 9, 2021
Manufacturing and Production Camallergy, UK, allergy

Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded …

News

Valo and ImmunoScape collaboration identifies immunogenic peptides for pan-coronavirus vaccine

March 9, 2021
Manufacturing and Production COVID-19, Valo Therapeutics, immunoscape, vaccines

Immunotherapy platform developer Valo Therapeutics has successfully completed a collaboration with the biotechnology company ImmunoScape to identify immunogenic peptides for …

News
novartis_window

Novartis’ canakinumab fails to improve lung cancer survival in Phase III study

March 9, 2021
Manufacturing and Production Cancer, Novartis, lung cancer

Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …

News
credit_-_daniel_leal-olivas-afp

CHMP recommends Lilly’s bamlanivimab for COVID-19 patients

March 8, 2021
Sales and Marketing COVID-19, EMA, Eli Lilly

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …

News
dw-anzcxqaqavhl

FDA grants Priority Review to Korsuva for CKD-associated pruritis

March 8, 2021
Sales and Marketing Cara Therapeutics, FDA, Korsuva

The FDA has accepted and granted Priority Review for the new drug application (NDA) for Cara Therapeutics’ Korsuva (difelikefalin) solution …

News

NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies

March 8, 2021
Sales and Marketing NICE, spinal muscular atrophy

NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …

News
landing-hero-images1

ViiV presents positive long-term data for combined HIV treatment

March 8, 2021
Sales and Marketing HIV, ViiV Healthcare

ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …

News
roche__tree

Roche voluntarily withdraws Tecentriq’s US bladder cancer indication

March 8, 2021
Sales and Marketing Cancer, Roche, bladder cancer, tecentriq

Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …

News
Pharmafile's top 10 news roundup

Pharmafile.com’s top 10 news stories of the week

March 5, 2021
Medical Communications COVID, COVID-19, COVID-19 vaccine, news roundup, pharma news, roundup

The last week has seen its fair share of COVID-19 vaccine developments; Bharat Biotech’s candidate was found to be 81% …

News

FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease

March 5, 2021
Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis

Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …

News
amgen_flag

Amgen to acquire Five Prime Therapeutics for approximately $1.9bn

March 5, 2021
Medical Communications Amgen, Cancer, five prime

Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of …

News

Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine

March 5, 2021
Medical Communications COVID-19, CureVac, Novartis, vaccines

CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …

News
houses_of_parliament_london_7654658782

UK government invests £5m in COVID-19 mRNA vaccine library

March 5, 2021
Medical Communications COVID-19, CPI, government, vaccines

The Centre for Process Innovation (CPI) has received a £5 million investment from the UK government, to support the development …

News
Takeda building

Takeda agree $856m deal with Ovid to take over soticlestat development

March 4, 2021
Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat

Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …

News

Beyond Batten Disease Foundation partners with Actelion on development of combination treatment

March 4, 2021
Actelion, Batten disease, Janssen

Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025